Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
September 05, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
August 14, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Provides Business Update and Reports Q2 2023 Financial Results
August 10, 2023 16:10 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023
July 31, 2023 16:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
July 24, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
July 19, 2023 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS and LOUISVILLE, Ky., July 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of...
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
July 17, 2023 06:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
July 10, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
June 28, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...